BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 17-Nov-2021

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 18.11.2021 to 21.11.2021. Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2021.

SQURPHARMA 15-Nov-2021

(cont. of SQURPHARMA): The Company has informed that growth in business volume and efficient utilization of working capital along with reduction in tax expense resulted in increased Consolidated Net Operating Cash Flow Per Share. (end)

SQURPHARMA 15-Nov-2021

(Q1 Un-audited): Consolidated EPS was Tk. 5.64 for July-September 2021 as against Tk. 4.44 for July-September 2020; Consolidated NOCFPS was Tk. 6.61 for July-September 2021 as against Tk. 3.30 for July-September 2020. Consolidated NAV per share was Tk. 108.71 as on September 30, 2021 and Tk. 102.54 as on June 30, 2021. (cont.)

SQURPHARMA 08-Nov-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.

SQURPHARMA 24-Oct-2021

(Continuation news of SQURPHARMA): which allowed us to obtain a healthy 7.63% increment in other income compared to last year's negative growth of 3.80%. Furthermore, the reduced corporate tax rate (22.5% from last year's 25%) for publicly listed entities for the concerned financial year (2020-21) helped us reducing tax expenses which in turn resulted in the increment of EPS. (end)

SQURPHARMA 24-Oct-2021

(Continuation news of SQURPHARMA): The overall impact was a good 11% growth in gross profit which has contributed towards earning a good EPS. Additionally, our prudent investment decision has paid off quite well. We have been able to earn a significant amount of other income in form of dividend, gain on bonds and marketable securities, interest etc. (please see note 21 of standalone annual report) (cont. 2)

SQURPHARMA 24-Oct-2021

Dividend Declaration (Additional Information): The Company has further informed that the Clarification on increase in EPS are as follows: The growth in our core business i.e. sales of pharmaceutical products has positively affected the EPS for the current year. Moreover, proficient usage of raw materials and optimized utilization of manufacturing overhead while maintaining stringent health and safety measurements to prevent Covid-19 has helped us maintaining a good Cost of Goods Sold for the year. (cont.1)

SQURPHARMA 24-Oct-2021

There will be no price limit on the trading of the shares of the Company today (24.10.2021) following its corporate declaration.

SQURPHARMA 24-Oct-2021

(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 17.99, Consolidated NAV per share of Tk. 102.54 and Consolidated NOCFPS of Tk. 12.43 for the year ended on June 30, 2021 as against Tk. 15.07, Tk. 87.28 and Tk. 12.14 respectively for the same period of the previous year. (end)

SQURPHARMA 24-Oct-2021

The Board of Directors has recommended 60% cash dividend for the year ended on June 30, 2021. The Board has also approved Tk. 300.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 15.12.2021, Time: 10:00 AM, Venue: Digital Platform. Record Date: 22.11.2021. (cont.1)

Previous Next page